TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1111464

Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of prednisone and fluoxymesterone
Number of subjects: 73

Group type: COMPARATOR
Intervention: No poor-risk factors
Number of subjects: 73

Group type: COMPARATOR
Intervention: At least one poor-risk factor
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen level
Number of subjects: 73
Study: 31911341

Group type: EXPERIMENTAL
Intervention: Therapy stratified by endotype (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified (intervention group)
Number of subjects: 0
Study: 31762898

Group type: EXPERIMENTAL
Intervention: Placental impression smears
Number of subjects: 491

Group type: COMPARATOR
Intervention: Histology
Number of subjects: 491
Study: 28929577

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25981528

Group type: EXPERIMENTAL
Intervention: Periodontal treatment with customized information and education
Number of subjects: 152
Study: 23864139

Group type: EXPERIMENTAL
Intervention: Radon spa therapy
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Radon spa therapy in OA patients
Number of subjects: 681

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 681
Study: 21612644

Group type: EXPERIMENTAL
Intervention: Acupuncture in RCT setting
Number of subjects: 54

Group type: COMPARATOR
Intervention: Acupuncture in usual practice
Number of subjects: 54
Study: 19883342

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (PoCT)
Number of subjects: 4381

Group type: COMPARATOR
Intervention: Pathology laboratory testing
Number of subjects: 4381
Study: 16554580

Group type: EXPERIMENTAL
Intervention: Chemotherapy with an investigational drug
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measurement of the maximal diameter of the single largest lesion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple‐lesion measurements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single‐lesion measurements
Number of subjects: 30
Study: 15243765

Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle ergometer (4 sessions per week, 45 min duration) for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 11375828

Group type: EXPERIMENTAL
Intervention: IV injection of 2 g propacetamol every 6 h for 3 days after surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 42
Study: 9404448

Group type: COMPARATOR
Intervention: rhGH therapy (0.25 IU/kg/week sc)
Number of subjects: 148

Group type: COMPARATOR
Intervention: rhGH therapy
Number of subjects: 148
Study: 12061306

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (1.2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2907896

Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Number of subjects: 243

Group type: COMPARATOR
Intervention: GnRH (gonadotropin releasing hormone)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 29709558

Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Non-bursectomy (omentectomy alone)
Number of subjects: 1204
Study: 28835465

Group type: EXPERIMENTAL
Intervention: Total modified Sharp/van der Heijde Scores (mSvdHS)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Joint space narrowing (JSN)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Erosions (ERO)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: mSvdHS in remission analyses
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: JSN in remission analyses
Number of subjects: 363
Study: 26142691

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 164
Study: 23771585

Group type: EXPERIMENTAL
Intervention: Monocular viewing
Number of subjects: 3

Group type: COMPARATOR
Intervention: Binocular viewing
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Right-hand selection with covered right eye leading
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Left-hand selection
Number of subjects: 3
Study: 19450946

Group type: EXPERIMENTAL
Intervention: Proper setup of SIR (manometer and pop-off valve closed)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Improper setup of SIR (pop-off valve open)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Improper setup of SIR (manometer open)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Improper setup of SIR (both open)
Number of subjects: 5
Study: 18294761

Group type: EXPERIMENTAL
Intervention: Electrostimulated acupuncture (EA) weekly for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA) weekly for 12 weeks
Number of subjects: 31
Study: 16877657

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 13678914

Group type: EXPERIMENTAL
Intervention: Optimal PTCA (balloon angioplasty)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Routine stenting
Number of subjects: 2082
Study: 11225999

Group type: EXPERIMENTAL
Intervention: Fludarabine, mitoxantrone, and dexamethasone (FND) combined with rituximab and maintenance alpha interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludarabine, mitoxantrone, and dexamethasone (FND) alone
Number of subjects: 0
Study: 9090580

Group type: EXPERIMENTAL
Intervention: Breath-hold T1-weighted FLASH sequence
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Breath-hold T2-weighted TSE sequence
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-breath-hold T1-weighted SE sequence
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-breath-hold T2-weighted SE sequence
Number of subjects: 120
Study: 8405626

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pethidine 75 mg
Number of subjects: 90
Study: 3983422

Group type: EXPERIMENTAL
Intervention: Misonidazole (1 g/m2, total 13-14 g/m2) given on every irradiation day
Number of subjects: 179

Group type: COMPARATOR
Intervention: Radiotherapy (3 daily fractions of 1.6 Gy for 2 weeks, total dose 48 Gy, boost to about 70 Gy after 3-4 weeks)
Number of subjects: 179
Study: 31265730

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Azathioprine (IFX 0 mg/kg)
Number of subjects: 1273
Study: 29754251

Group type: EXPERIMENTAL
Intervention: Medication reconciliation and counselling intervention delivered by a pharmacist
Number of subjects: 587

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 587
Study: 26393904

Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.4 mg and tolterodine 4 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monotherapy (tamsulosin 0.4 mg and placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 80
Study: 24613655

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 22315282

Group type: EXPERIMENTAL
Intervention: Low-dose BH4 (400 mg/d)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-dose BH4 (700 mg/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 19897803

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 μg
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Systemic hydromorphone 1 mg IV and 1 mg IM
Number of subjects: 692

Group type: COMPARATOR
Intervention: Neuraxial analgesia (combined spinal-epidural)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 692
Study: 18569914

Group type: EXPERIMENTAL
Intervention: Oral 300,000 IU cholecalciferol supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 40
Study: 15747245

Group type: EXPERIMENTAL
Intervention: rA2cp248/404/1030 Delta SH
Number of subjects: 44

Group type: COMPARATOR
Intervention: rA2cp248/404 Delta SH
Number of subjects: 44
Study: 11909785

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study: 10695779

Group type: EXPERIMENTAL
Intervention: 240 mg single dose of oral dihydroartemisinin (DHA)
Number of subjects: 8
Study: 8961361

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 325 mg daily for 1 year
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 186
Study: 1901203

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium-imipramine combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6349943

Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate 0.2 percent ointment
Number of subjects: 145
Study: 31115908

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg Q2W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg Q2W (global population)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab (general)
Number of subjects: 0
Study: 27188759

Group type: EXPERIMENTAL
Intervention: Electronic messaging intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no electronic messaging)
Number of subjects: 200
Study: 27697128

Group type: EXPERIMENTAL
Intervention: Nurse-initiated telephone follow-up after discharge
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 224
Study: 25091664

Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^5.0 FFU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^5.8 FFU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^6.4 FFU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rotateq
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23176247

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids, gamma-linolenic acid, and antioxidants
Number of subjects: 272

Group type: COMPARATOR
Intervention: isocaloric control
Number of subjects: 272
Study: 19717345

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n=251)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Endarterectomy (n=253)
Number of subjects: 504
Study: 17610441

Group type: EXPERIMENTAL
Intervention: Telephonic social care management (CA Program)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 781
Study: 16389497

Group type: EXPERIMENTAL
Intervention: Housing First program
Number of subjects: 197

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 197
Study: 11917277

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg) administered before each chemotherapy cycle in the phase II trial and before carboplatin administration in the intensification trial.
Number of subjects: 646

Group type: COMPARATOR
Intervention: Conventional radiotherapy (60 Gy) and carboplatin (700 mg/m² cumulative dose) without amifostine in the control group of the phase II trial.
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Carboplatin (70 mg/m²) on specific days during radiotherapy in the intensification trial.
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Amifostine combined with RCT in the long-term follow-up investigation.
Number of subjects: 646

Group type: COMPARATOR
Intervention: RCT without cytoprotection in the long-term follow-up investigation.
Number of subjects: 646
Study: 10498383

Group type: EXPERIMENTAL
Intervention: Digital controller
Number of subjects: 6

Group type: COMPARATOR
Intervention: Analog controller
Number of subjects: 6
Study: 7503066

Group type: EXPERIMENTAL
Intervention: DCLHb 25 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DCLHb 50 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DCLHb 100 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DCLHb (all doses)
Number of subjects: 18
Study: 2048706

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study: 7262758

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conray EV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tele-brix 300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amipaque
Number of subjects: 0
Study: 31609433

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 27658562

Group type: EXPERIMENTAL
Intervention: Triclosan-containing sutures
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Ordinary absorbing sutures
Number of subjects: 1633
Study: 25456838

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 42
Study: 23849608

Group type: EXPERIMENTAL
Intervention: Autopolymerized acrylic resin with silanated attachment housings (APSAH)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Autopolymerized acrylic resin (APAR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Light‐polymerized acrylic resin (LPAR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Light‐polymerized acrylic resin with silanated attachment housings (LPSAH)
Number of subjects: 80
Study: 22448480

Group type: EXPERIMENTAL
Intervention: 4-glass test (Mearls and Stamey)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 2-glass test before finger rectal test (FRT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 3-glass test
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Original technique proposed by the authors
Number of subjects: 177
Study: 19504490

Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis (either UFH or LMWH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 14

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 14
Study: 28080292

Group type: EXPERIMENTAL
Intervention: endOclear device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 40
Study: 19731498

Group type: EXPERIMENTAL
Intervention: Brief alcohol-reduction intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage of change (SOC)
Number of subjects: 0
Study: 10699772

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 50
Study: 9330936

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (2 ng/kg/min for 8 hours)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Iloprost (9 infusions over 6 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day for 6 months)
Number of subjects: 26
Study: 8104656

Group type: EXPERIMENTAL
Intervention: Enteric-coated sulphasalazine (SASP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3519382

Group type: EXPERIMENTAL
Intervention: Defibrotide (200 mg IV four times a day for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30289950

Group type: EXPERIMENTAL
Intervention: SCARB1 SNP rs10846744
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lp‐PLA2 activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darapladib (Lp‐PLA2 inhibitor)
Number of subjects: 0
Study: 26605966

Group type: EXPERIMENTAL
Intervention: BW10-Group (feedback provided when errors were larger than 10°)
Number of subjects: 48

Group type: COMPARATOR
Intervention: BW0-Group (100% frequency of feedback)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: YokedBW10-Group (matched to feedback schedule of BW10-Group)
Number of subjects: 48
Study: 25325204

Group type: EXPERIMENTAL
Intervention: 200 IU/day of vitamin D
Number of subjects: 60

Group type: COMPARATOR
Intervention: 400 IU/day of vitamin D
Number of subjects: 60
Study: 22543771

Group type: EXPERIMENTAL
Intervention: Body temperature fluid (BTF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Room temperature fluid (RTF)
Number of subjects: 86
Study: 20615885

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Other carcinogenic HPV
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HPV31
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HPV52
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HPV51
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: HPV16-positive CIN3
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Other carcinogenic HPV genotypes
Number of subjects: 608
Study: 18415679

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) testing for bacterial gastroenteritis
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing for bacterial gastroenteritis
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: PCT levels in patients with renal impairment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: PCT levels in inflammatory bowel disease (IBD) patients
Number of subjects: 153
Study: 15712536

Group type: EXPERIMENTAL
Intervention: Serial lumbar puncture and acetazolamide combination
Number of subjects: 18
Study: 12540416

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk drink (65 mL with Lactobacillus GG, Bifidobacterium sp B420, Lactobacillus acidophilus 145, and Streptococcus thermophilus; n = 108)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard yogurt (180 g; n = 101)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk drink
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard yogurt
Number of subjects: 209
Study: 10813378

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8858355

Group type: EXPERIMENTAL
Intervention: BSS Plus with heparin and dexamethasone (HD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: BSS Plus (control)
Number of subjects: 62
Study: 1516609

Group type: EXPERIMENTAL
Intervention: Oral alprazolam (1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual alprazolam (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (sublingual)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both routes of alprazolam (oral and sublingual)
Number of subjects: 12
Study: 6384291

Group type: EXPERIMENTAL
Intervention: Ultraviolet A (UVA) added to ultraviolet B (UVB) phototherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultraviolet B (UVB) phototherapy alone
Number of subjects: 25
Study: 31734125

Group type: EXPERIMENTAL
Intervention: Culturally‐tailored educational curriculum around stroke risk reduction
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 225
Study: 30060707

Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Gelatin sponge patch
Number of subjects: 141

Group type: COMPARATOR
Intervention: Observation (spontaneous healing)
Number of subjects: 141
Study: 27219531

Group type: EXPERIMENTAL
Intervention: Patient-rated therapeutic alliance
Number of subjects: 209

Group type: COMPARATOR
Intervention: Therapist-rated therapeutic alliance
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Two well-validated measures of depression symptom severity
Number of subjects: 209
Study: 24669146

Group type: EXPERIMENTAL
Intervention: Rose‐K contact lenses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soper contact lenses
Number of subjects: 60
Study: 22311004

Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (V/HCTZ)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Valsartan (V)
Number of subjects: 384
Study: 20047095

Group type: EXPERIMENTAL
Intervention: idarubicin and cytosine arabinoside (IDR/Ara-C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: low-dose cytosine arabinoside and aclarubicin (CA)
Number of subjects: 120
Study: 18663736

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16297779

Group type: EXPERIMENTAL
Intervention: CytoGam (n = 13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 23
Study: 12454227

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diclofenac infusion
Number of subjects: 15
Study: 10527007

Group type: EXPERIMENTAL
Intervention: Lottery incentive
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Short questionnaire (one page)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Long questionnaire (seven pages)
Number of subjects: 440
Study: 8719592

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 1952037

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with extubation during anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane anesthesia with extubation during anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with awake extubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane anesthesia with awake extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extubation during anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Awake extubation
Number of subjects: 40